EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY 4.0

Proof of concept for a superior therapeutic index of corticosterone compared with hydrocortisone in patients with congenital adrenal hyperplasia

Catriona J Kyle, Luke D Boyle, Mark Nixon, Natalie Z M Homer, Joanna P Simpson, Alison Rutter, Lynne E Ramage, Alexandra Kelman, Ellen Marie Freel, Ruth Andrew iD, Brian R Walker, Roland H Stimson iD

European Journal of Endocrinology · 2024

DOI: 10.1093/ejendo/lvae144 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Endocrinology, 2024. Verfasst von Catriona J Kyle und 11 weiteren Autor:innen. Beteiligte Einrichtung: University/BHF Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, EH16 4TJ, United Kingdom. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital, Hydrocortisone, Cross-Over Studies, Corticosterone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, SCIEX QTRAP 6500+instrument, NHS Research Scotland for the Mass Spectrometry Core.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Outcomes are poor for patients with congenital adrenal hyperplasia (CAH), in part due to the supraphysiological glucocorticoid doses required to control adrenal androgen excess. Hydrocortisone (ie, cortisol) is the recommended glucocorticoid for treatment of CAH. However, the other endogenous glucocorticoid in humans, corticosterone, is actively transported out of metabolic tissues such as adipose tissue and muscle, so we hypothesized that corticosterone could control adrenal androgens while causing fewer metabolic adverse effects than hydrocortisone.

Methods

Thirteen patients (8 female, 5 male) with CAH due to 21-hydroxylase deficiency completed a randomized placebo-controlled crossover study comparing 5 h intravenous infusions of either hydrocortisone, corticosterone or placebo. 6-6[2H]2-glucose and 1,1,2,3,3-[2H]5-glycerol were infused to measure glucose and glycerol kinetics, and blood samples were collected throughout. Subcutaneous abdominal adipose tissue biopsies were obtained at the end of each infusion.

Results

During the infusion, corticosterone and hydrocortisone similarly reduced ACTH, 17α-hydroxyprogesterone, androstenedione, and testosterone (in females only) compared with placebo. Despite achieving circulating corticosterone concentrations ∼2.5-fold higher than hydrocortisone, by T + 300 min hydrocortisone but not corticosterone increased glucose and insulin concentrations and reduced 6-6-[2H]2-glucose clearance compared with placebo. Hydrocortisone increased mRNA levels of the glucocorticoid regulated transcript PER1 in adipose to a greater extent than corticosterone.

Conclusions

Corticosterone acutely controls biochemical markers of androgen excess similarly to hydrocortisone but without inducing markers of glucocorticoid “toxicity” in CAH. These data demonstrate proof of concept that corticosterone may be a safer glucocorticoid replacement than current medications, although further research is required to assess the longer-term effects of corticosterone replacement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Hyperplasia, CongenitalHydrocortisoneCross-Over StudiesCorticosteroneHumansFemaleMaleAdultAdolescentYoung AdultProof of Concept StudyTestosteroneGlucocorticoidsAndrostenedioneChildInfusions, Intravenous

Stichwörter der Autor:innen

androgenscongenital adrenal hyperplasiacorticosteronehydrocortisoneinsulin resistance

Substanzen

HydrocortisoneCorticosteroneTestosteroneGlucocorticoidsAndrostenedione

Autor:innen und Institutionen

  • University/BHF Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, EH16 4TJ, United Kingdom.
  • Queen Elizabeth University Hospital, Glasgow, G51 4TF, United Kingdom.
  • Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, NE4 5PL, United Kingdom.

ORCID-Profile: Ruth Andrew, Roland H Stimson

Förderung

  • Wellcome Trust
  • SCIEX QTRAP 6500+instrument
  • NHS Research Scotland for the Mass Spectrometry Core
  • International Fund raising for research in Congenital Adrenal Hyperplasia
  • Chief Scientist Office
  • ThermoScientific Quantum GC-MS/MS
  • British Heart Foundation

Zitieren

APA

Kyle, C. J., Boyle, L. D., Nixon, M., Homer, N. Z. M., Simpson, J. P., Rutter, A., Ramage, L. E., Kelman, A., Freel, E. M., Andrew, R., Walker, B. R., & Stimson, R. H. (2024). Proof of concept for a superior therapeutic index of corticosterone compared with hydrocortisone in patients with congenital adrenal hyperplasia. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvae144

Vancouver

Kyle CJ, Boyle LD, Nixon M, Homer NZM, Simpson JP, Rutter A, et al. Proof of concept for a superior therapeutic index of corticosterone compared with hydrocortisone in patients with congenital adrenal hyperplasia. European Journal of Endocrinology. 2024. doi:10.1093/ejendo/lvae144

BibTeX
@article{Kyle2024,
  author = {Kyle, Catriona J and Boyle, Luke D and Nixon, Mark and Homer, Natalie Z M and Simpson, Joanna P and Rutter, Alison and Ramage, Lynne E and Kelman, Alexandra and Freel, Ellen Marie and Andrew, Ruth and Walker, Brian R and Stimson, Roland H},
  title = {Proof of concept for a superior therapeutic index of corticosterone compared with hydrocortisone in patients with congenital adrenal hyperplasia},
  journal = {European Journal of Endocrinology},
  year = {2024},
  doi = {10.1093/ejendo/lvae144}
}
Kostenlos starten →